News and press

“I am delighted to have joined this dynamic, growing and unique company and leading the people, communications and marketing agendas to take the company to the next level."

On 24th March 1882, a German scientist discovered the mycobacterium that causes Tuberculosis - the same date each year is now World Tubercolsis Day.

Pain, purpura and curly hairs - the symptoms of a man who the Nutristasis Unit diagnosed as having scurvy, read the full case study here.

Today marks the start of Nutrition and Hydration Awareness Week, learn more about our Nutristasis Unit - an industry leading centre of excellence in profiling vitamin status and diagnosing deficiencies.

Therapeutic drug monitoring (TDM) of infliximab (IFX) is useful in patients with inflammatory bowel disease (IBD). Therapeutic cut-offs to predict active disease and the influence of thiopurines on drug levels (DL) according to 6-thioguanine nucleotide (TGN) are not defined. There is limited data on the utility of free anti-drug antibodies (ADAb) against total ADAb. We assessed the utility of TDM of IFX in IBD using a commercially available ELISA and investigated the influence of TGNs on DL and free/total ADAb.

Some, but not all, studies have demonstrated a relationship between therapeutic drug monitoring (TDM) of adalimumab (ADA) and outcomes in Crohn's disease (CD). We evaluated the utility of TDM of ADA in patients with CD using two commercially-available ELISA.

Working in collaboration with our partners at Guy's and St. Thomas' NHS Foundation Trust, we have been nominated for a BMJ Patient Safety Award for our work in preimplantation genetic diagnosis.

Today is World Cancer Day, read this story to for some key statistics as well as to find out how Viapath contributes to both cancer care and developing the future of cancer diagnostics.